CD8A and neoplasm: The intracellular delivery efficiency of PLGA (FITC-siRNA)-NPs increased in a dose-dependent manner in immune cells (CD8+ T cells and DCs) and tumor cells (TC-1 and EG7) (p<0.001, figure 1H).